The factors predicting development of serious infections in ANCA-associated vasculitis

##plugins.themes.themeTen.article.main##

Emine Uslu Yurteri
Serdar Sezer
Murat Torgutalp
Mucteba Enes Yayla
Didem Sahin Eroglu https://orcid.org/0000-0003-3558-5400
Ilyas Ercan Okatan
Ayse Bahar Kelesoglu Dincer
Emine Gozde Aydemir Guloksuz
Mehmet Levent Yuksel
Tahsin Murat Turgay
Askin Ates
Gulay Kinikli

Keywords

Infection, ANCA, vasculitis, mortality

Abstract

Background: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease usually involving small vessels and progressing with necrotizing inflammation. Treatment requires long-term use of immunosuppressive agents to inhibit disease activity. Serious infections (SIs) are a common complication in AAV.


Objective: The aim of this study was to identify the risk factors for serious infections which required hospitalization in patients with AAV.


Methods: In this retrospective cohort study., we included 84 patients admitted to the Ankara University Faculty of Medicine in the last 10 years with a diagnosis of AAV.


Results: In 42 (50%) of 84 patients followed up with the diagnosis of AAV, an infection requiring hospitalization was identified. The patients’ total corticosteroid dose, use of pulse steroids, induction regimen, levels of C-reactive protein (CRP) and the presence of pulmonary and renopulmonary involvement were found to be associated with the frequency of infection (p=0.015, p=0.016, p=0.010, p=0.03, p= 0.026 and p=0.029, respectively). In multivariable analysis, it was found that renopulmonary involvement (p=0.002, HR=4.95, 95% CI= 1.804-13.605), age of over 65 (p=0.049, HR=3.37, 95% CI=1.004-11.369) and high CRP levels (p=0.043, HR=1.006, 95% CI=1.000-1.011) constituted independent predictors of serious infection risk.


Conclusion: The frequency of infection is known to be increased in ANCA-associated vasculitis. Our study showed that renopulmonary involvement, age and elevated CRP levels on admission are independent risk factors of infection.

Abstract 567 | PDF Downloads 395

References

1 Jeanette J, Falk R, Bacon P. Nomenclature of Vasculitides. 2012 revised International Chapel Hill Consensus Conference. Arthritis & Rheumatism 2013;65:1.
2 Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology 2014;53(12):2306-9.
3 Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Care & Research 2004;51(1):83-91.
4 Mohammad AJ, Segelmark M, Smith R, et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. The Journal of rheumatology 2017;44(10):1468-75.
5 Harper L, Savage C. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology 2005;44(4):495-501.
6 McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clinical journal of the American Society of Nephrology 2012;7(2):240-7.
7 Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis & Rheumatism 1990;33(8):1065-7.
8 Luqmani R, Bacon P, Moots R, et al. Birmingham vasculitis activity score (BVAS) Dim system necrotizinig vasculitis. QJM: An International Journal of Medicine 1994;87(11):671-8.
9 Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68(12):1827-32.
10 Stone JH, Hoffman GS, Merkel PA, et al. A disease‐specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis & Rheumatism 2001;44(4):912-20.
11 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-83.
12 Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Annals of the rheumatic diseases 2009;68(5):658-63.
13 Gayraud M, Guillevin L, Le Toumelin P, et al. Long‐term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg‐Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis & Rheumatism 2001;44(3):666-75.
14 Reinhold‐Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long‐term outcome in 155 patients. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2000;43(5):1021-32.
15 Troncoso JÁ, Iannaccone Z, Valiente EÁ, et al. AB0673 Anca-associated vasculitis and infections: retrospective analysis in a referral centre. In: BMJ Publishing Group Ltd; 2018.
16 Waki D, Nishimura K, Kadoba K, Mukoyama H, Saito R, Yokota T. FRI0490 Mortality and early severe infection in patients with anca-associated vasculitis. In: BMJ Publishing Group Ltd; 2018.
17 Yamaguchi M, Katsuno T, Iwagaitsu S, et al. Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis. BMC Infectious Diseases 2019;19(1):1-7.
18 Yang L, Xie H, Liu Z, et al. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC nephrology 2018;19(1):1-7.
19 Yoo J, Jung SM, Song JJ, Park YB, Lee SW. Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Clin Rheumatol 2018;37(8):2133-41.
20 Rathmann J, Jayne D, Segelmark M, Jonsson G, Mohammad AJ. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford) 2021;60(6):2745-54.
21 Huffnagle G, Dickson R, Lukacs N. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 2017; 10 (2): 299–306. In; 2016.
22 Hauser AB, Stinghen AE, Kato S, et al. Characteris Tics and Causes of Immune Dysfunction Related to Uremia and Dialysis. Peritoneal Dialysis International 2008;28(3_suppl):183-7.
23 Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Annals of the rheumatic diseases 2011;70(3):488-94.
24 Garcia-Vives E, Segarra-Medrano A, Martinez-Valle F, Agraz I, Solans-Laque R. Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody–associated vasculitis: influence on the disease outcome. The Journal of Rheumatology 2020;47(3):407-14.
25 Lai Q-y, Ma T-T, Li Z-y, Chang D-y, Zhao M-H, Chen M. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. The Journal of rheumatology 2014;41(9):1849-55.
26 Little MA, Nightingale P, Verburgh CA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Annals of the rheumatic diseases 2010;69(6):1036-43.
27 Pinti M, Appay V, Campisi J, et al. Aging of the immune system: focus on inflammation and vaccination. European journal of immunology 2016;46(10):2286-301.
28 Morishita M, Sada K-E, Matsumoto Y, et al. Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Plos one 2019;14(7):e0218705.
29 Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford) 2021;60(8):3553-64.
30 Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335(1):16-20.

Most read articles by the same author(s)